Alexis Vrachimis1, Christian Wenning1, Joachim Gerß2, Henning Dralle3, Mohammad Vaez Tabassi1, Otmar Schober1, Burkhard Riemann1. 1. Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, Münster, Germany. 2. Institute of Biostatistics and Clinical Research, University Hospital Münster, Albert-Schweitzer-Campus 1, Münster, Germany. 3. Department of General, Visceral and Vascular Surgery, University Hospital, Medical Faculty, University of Halle-Wittenberg, Halle/Saale, Germany.
Abstract
BACKGROUND AND OBJECTIVES: To investigate if patients with thyroid carcinoma having N1a disease are at the same risk with N1b using the collective of the well-defined European prospective Multicentre Study Differentiated Thyroid Cancer (MSDS). METHODS:Overall (OS) and event free survival (EFS) were calculated. Cox multivariable regression analysis was performed in order to calculate Hazard ratios (HR). RESULTS:EFS was significantly decreased only in patients with N1b metastasis as compared to N0 patients and became worse when N1a was concomitantly affected. A superior survival in favor of N1a patients as compared to N1b patients with regard to EFS was also observed. The patients having N1a disease showed no differences in the EFS as compared to N0. OS did not differ significantly in any of the groups. There was an increased HR for events with regards to histology, T-stage, tumor size, UICC stage and cervical lymph node metastasis. Tumor size showed a significantly increased risk for OS. CONCLUSIONS:Patients with pT3b and pT4a tumors with N1b are of higher risk for relapse, albeit not affecting overall survival. Patients with N1a are of no higher risk. The risk stratification of these patients may be adapted accordingly.
RCT Entities:
BACKGROUND AND OBJECTIVES: To investigate if patients with thyroid carcinoma having N1a disease are at the same risk with N1b using the collective of the well-defined European prospective Multicentre Study Differentiated Thyroid Cancer (MSDS). METHODS: Overall (OS) and event free survival (EFS) were calculated. Cox multivariable regression analysis was performed in order to calculate Hazard ratios (HR). RESULTS: EFS was significantly decreased only in patients with N1b metastasis as compared to N0 patients and became worse when N1a was concomitantly affected. A superior survival in favor of N1a patients as compared to N1b patients with regard to EFS was also observed. The patients having N1a disease showed no differences in the EFS as compared to N0. OS did not differ significantly in any of the groups. There was an increased HR for events with regards to histology, T-stage, tumor size, UICC stage and cervical lymph node metastasis. Tumor size showed a significantly increased risk for OS. CONCLUSIONS:Patients with pT3b and pT4a tumors with N1b are of higher risk for relapse, albeit not affecting overall survival. Patients with N1a are of no higher risk. The risk stratification of these patients may be adapted accordingly.
Authors: Leyre Lorente-Poch; Juan Sancho; Jose Luis Muñoz; Lander Gallego-Otaegui; Carlos Martínez-Ruiz; Antonio Sitges-Serra Journal: Langenbecks Arch Surg Date: 2017-01-07 Impact factor: 3.445
Authors: Alexis Vrachimis; Matthias Christian Burg; Christian Wenning; Thomas Allkemper; Matthias Weckesser; Michael Schäfers; Lars Stegger Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-29 Impact factor: 9.236
Authors: Hye In Kim; Tae Hyuk Kim; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim; Young Lyun Oh; Soo Yeon Hahn; Jung Hee Shin; Hye Won Jang; Young Nam Kim; Hosu Kim; Hyeon Seon Ahn; Kyunga Kim; Sun Wook Kim; Jae Hoon Chung Journal: Cancer Med Date: 2017-08-31 Impact factor: 4.452